Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Randomized Controlled Trial

Status: Recruiting
Location: See all (29) locations...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed. This confirmation is mandatory to validate the improvement of the prognosis of EA-IPF under this treatment but also to search for unsuspected deleterious effects as it has been shown with immunosuppressants in stable idiopathic pulmonary fibrosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient is ≥ 18 years of age

• IPF or IPF (likely) diagnosis defined on 2018 international recommendations

• Definite or suspected Acute Exacerbation defined by the international working group criteria after exclusion of alternative diagnoses of acute worsening

• \*The criteria of IPF-AE are as follows:

⁃ Previous or concurrent diagnosis of IPF (a)

⁃ Acute worsening or development of dyspnea typically \< 1-month duration

⁃ Computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia pattern (b)

⁃ Deterioration not fully explained by cardiac failure or fluid overload Patients who fail to meet all 4 criteria due to missing computed tomography should be considered as having suspected Acute Exacerbation.

∙ If the diagnosis of IPF is not previously established, this criterion can be met by the presence of radiologic and/or histopathologic changes consistent with usual interstitial pneumonia pattern on the current evaluation.

‣ If no previous computed tomography is available, the qualifier new can be dropped from the third criterion.

• For women of childbearing age: efficient contraception for the duration of the study\*

• \*Effective contraception is defined as any contraceptive method that is used consistently and appropriately and has a low failure rate (i.e., less than 1% per year)

• Affiliation to the social security

• Patient able to understand and sign a written informed consent form or in case of incapacity of the patient to a relative whom understand and sign a written informed consent form

Locations
Other Locations
France
CHU ANgers
RECRUITING
Angers
CHU de Besancon
RECRUITING
Besançon
Hôpital Avicenne
NOT_YET_RECRUITING
Bobigny
CHU BOrdeaux
RECRUITING
Bordeaux
CHU Caen
RECRUITING
Caen
CHU Clermont-Ferrand
NOT_YET_RECRUITING
Clermont-ferrand
CHIC
RECRUITING
Créteil
CHU de Dijon
RECRUITING
Dijon
CHU Grenoble
NOT_YET_RECRUITING
Grenoble
CHRU Lille
NOT_YET_RECRUITING
Lille
Hospices Civils de Lyon
RECRUITING
Lyon
Hôpital Nord
RECRUITING
Marseille
CHU de Montpellier
NOT_YET_RECRUITING
Montpellier
CHU Nancy
RECRUITING
Nancy
CHU de Nantes
NOT_YET_RECRUITING
Nantes
CHU Nice
NOT_YET_RECRUITING
Nice
Hôpital Bichat
RECRUITING
Paris
Hôpital Européen Georges Pompidou
RECRUITING
Paris
Hôpital FOCH
NOT_YET_RECRUITING
Paris
Hôpital Kremiln Bicetre
RECRUITING
Paris
Hôpital Paris Saint-Joseph
RECRUITING
Paris
Hôpital Saint-Louis
NOT_YET_RECRUITING
Paris
Hôpital Tenon
RECRUITING
Paris
CHU Reims
RECRUITING
Reims
CHU Rennes
RECRUITING
Rennes
CHU Rouen
NOT_YET_RECRUITING
Rouen
CHU Strasbourg
NOT_YET_RECRUITING
Strasbourg
CHU Toulouse
RECRUITING
Toulouse
CHU Tours
NOT_YET_RECRUITING
Tours
Contact Information
Primary
Jean-Marc NACCACHE, MD
jmnaccache@ghpsj.fr
144126747
Backup
Helene BEAUSSIER, PharmD, PhD
crc@ghpsj.fr
144127883
Time Frame
Start Date: 2023-10-26
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 110
Treatments
Experimental: MethylPrednisone/Prednisone
* Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d) Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes. The commercialized form for methylprednisolone injectable solution is not imposed and is taken from the stock of each pharmacy of the participating centers.~* From day 4 to Day 30: Oral Prednisone slow tappering~ * 1 mg/kg/d for 7 days~ * 0.5 mg/kg/d for 7 days~ * 0.25 mg/kg/d for 7 days,~ * 10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8.
Placebo_comparator: Placebo
* Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo~* From Day 4 to Day 30: Oral Prednisone-Placebo
Sponsors
Leads: Fondation Hôpital Saint-Joseph

This content was sourced from clinicaltrials.gov